14 October 2021 – Poolbeg Pharma (AIM: POLB), ‘Poolbeg’ or the ‘Company’, a clinical stage infectious disease pharmaceutical company with a capital light clinical model, provides an update on new
7 October 2021 – Poolbeg Pharma (AIM: POLB), Poolbeg’ or the ‘Company’, a clinical stage infectious disease pharmaceutical company with a capital light clinical model, has partnered with leading global
To help indicate the strength of antibody response and possible immunity
Britain’s recovery from the COVID-19 pandemic sped up in April as lockdown measures eased, with the fastest monthly growth since July leaving output a record 27.6% higher than a year
Paris, France and Camberley, UK – 29 September 2020 – Novacyt, an international specialist in clinical diagnostics, announces that, further to the announcement on 27 July 2020, the Company has
Positive Coronavirus test results in shorter timescales
Avacta appoints BBI Solutions as manufacturing partner for the rapid SARS-CoV-2 antigen test being developed with Cytiva
Infectivity assays carried out in collaboration with Glasgow University show that Affimer reagents prevent infection of human cells by a SARS-COV-2 model virus
Highly specific prototype test detects the virus spike protein at clinically relevant concentrations
Braveheart is pleased to provide an update concerning the development of a COVID-19 test with the University of Sheffield.
LONDON/LOS ANGELES (Reuters) The outbreak has killed more than 3,400 people and spread across more than 90 nations, with seven countries reporting their first cases on Friday. The economic damage
